InflaRx (IFRX) AI Stock Analysis

• Market Cap: $57.07M
• Dividend Yield: N/A
• Average Volume (3M): 338.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: 178.84%
• EPS Growth: -40.60%
• Country: US
• Employees: 74
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 67,133,270
• 10 Day Avg. Volume: 430,289
• 30 Day Avg. Volume: 338,682
• PEG Ratio: -0.26
• Price to Book (P/B): 0.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.40
• Price Target Upside: 535.29% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 42 Neutral
• Price Target: $1.00 ▲(17.65%Upside)

InflaRx's overall stock score reflects significant financial challenges, with ongoing losses and negative cash flows being the primary concerns. Technical analysis provides a neutral outlook, while poor valuation metrics add further downside risk. The absence of earnings call data and corporate events does not alter the fundamentally weak position.

Positive Factors

Commercial Opportunities

Both CSU and HS are meaningful commercial opportunities.

Drug Development

INF904 is a potentially better C5aR inhibitor than FDA-approved Tavneos, suggesting an improved design based on available PK/PD data.

Financial Performance

The company's cash runway guidance could get extended, with cash, cash equivalents, and marketable securities reported at €65.7M.

Negative Factors

Clinical Trial Challenges

The Independent Data Monitoring Committee recommended the Phase 3 trial evaluating vilobelimab in PG be stopped due to lack of observed treatment effect.

Disappointment in Drug Development

The failure is a large disappointment for the company and patients, especially considering the paucity of other assets in development for PG.

InflaRx Business Overview & Revenue Model

Company Description

InflaRx (IFRX) is a clinical-stage biopharmaceutical company based in Germany, focused on discovering and developing anti-inflammatory therapeutics by targeting the complement system. The company's lead product candidate, vilobelimab, is a monoclonal antibody designed to inhibit the activity of C5a, a protein involved in the inflammatory response. InflaRx primarily operates within the biotechnology and pharmaceuticals sectors, with a focus on addressing severe and life-threatening inflammatory diseases.

How the Company Makes Money

InflaRx makes money primarily through the development and potential commercialization of its pipeline of therapeutic candidates targeting the complement system. Revenue streams include potential partnerships with larger pharmaceutical companies for co-development and commercialization, as well as licensing agreements that can provide upfront payments, milestone payments, and royalties on sales. Additionally, as InflaRx progresses its drug candidates through clinical trials and towards potential regulatory approval, the company may receive funding through grants or investment from private and public sources to support its research and development activities.

InflaRx Financial Statement Overview

Summary

InflaRx's financial performance is weak, highlighted by consistent negative cash flow and operating losses, leading to a score at the lower end of the scale. The balance sheet shows limited leverage but negative returns on equity, indicating significant challenges in profitability and cash flow management.

Income Statement

InflaRx's income statement shows significant challenges in profitability and revenue growth. The company has been operating at a loss with negative net income and gross profit margins. Although total revenue increased from 2023 to 2024, the net profit margin remains negative, reflecting continued financial strain.

Balance Sheet

The balance sheet highlights high equity levels relative to debt, but the company has been operating with net debt positions, suggesting better liquidity management. However, the return on equity is negative due to persistent net losses, pointing to concerns in generating returns for shareholders.

Cash Flow

InflaRx's cash flow statement indicates consistent negative operating cash flow and free cash flow, suggesting ongoing cash burn issues. The free cash flow to net income ratio is poor, pointing to challenges in converting earnings into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	165.79K	63.09K	0.00	0.00	0.00
Gross Profit	-3.15M	-469.17K	-585.85K	-696.14K	-664.03K
EBITDA	-45.55M	-42.06M	-31.29M	-46.90M	-32.47M
Net Income	-46.06M	-42.67M	-27.04M	-45.65M	-34.01M
Balance Sheet
Total Assets	76.02M	120.21M	102.40M	125.14M	88.22M
Cash, Cash Equivalents and Short-Term Investments	52.84M	90.27M	81.81M	83.41M	81.13M
Total Debt	805.09K	1.12M	1.36M	1.43M	559.04K
Total Liabilities	14.60M	17.63M	14.05M	19.86M	10.35M
Stockholders Equity	61.42M	102.58M	88.35M	105.28M	77.86M
Cash Flow
Free Cash Flow	-48.60M	-37.89M	-33.91M	-39.97M	-36.62M
Operating Cash Flow	-48.56M	-37.81M	-33.74M	-39.94M	-36.53M
Investing Cash Flow	52.36M	-17.70M	19.36M	-25.95M	21.36M
Financing Cash Flow	386.45K	52.99M	1.94M	61.58M	9.17M

InflaRx Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Negative. The current price of 0.85 is above the 20-day moving average (MA) of 0.84, below the 50-day MA of 1.02, and below the 200-day MA of 1.60, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 45.45 is Neutral, neither overbought nor oversold. The STOCH value of 40.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IFRX.

InflaRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VTGN	57 Neutral	$79.02M	―	-46.28%	―	-33.00%	54.91%
Sector *	50 Neutral	AU$2.62B	3.32	-57.47%	2.40%	36.73%	13.67%
CLSD	43 Neutral	$45.46M	―	91.63%	―	-55.47%	24.92%
IFRX	42 Neutral	$57.07M	―	-62.38%	―	178.84%	-40.60%
CABA	39 Underperform	$149.31M	―	-73.85%	―	―	-40.59%
JSPR	35 Underperform	$49.12M	―	-101.34%	―	―	21.40%